Refractory secondary thrombotic microangiopathy in two systemic disorders with remission after autologous haematopoietic stem cell transplantation: a case series
This case series reports that autologous haematopoietic stem cell transplantation (AHSCT) induced durable remission and organ recovery in two patients with refractory secondary thrombotic microangiopathy associated with systemic lupus erythematosus/antiphospholipid syndrome and a monoclonal gammopathy disorder, respectively, highlighting the potential of AHSCT as a therapeutic option for severe, treatment-resistant cases despite the lack of persistent conventional haematological markers of disease activity.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human body's immune system is designed to protect us, but sometimes it turns against its own tissues, creating a chaotic storm of inflammation and blood clots. In a rare and dangerous condition called thrombotic microangiopathy, tiny blood vessels throughout the body become clogged with clots, starving organs of oxygen and causing them to fail. This can happen as a complication of other serious autoimmune diseases or blood disorders. When the body's standard defenses—powerful drugs that suppress the immune system or therapies that filter the blood—fail to stop this internal bleeding and clotting, doctors face a desperate situation. The question becomes whether it is possible to completely restart the immune system to stop the attack before the damage becomes permanent.
Two patients, a young woman and a middle-aged man, faced exactly this crisis. Both suffered from severe, life-threatening versions of these blood vessel disorders that did not respond to conventional treatments. The young woman had a complex autoimmune disease that caused her blood to clot uncontrollably, leading to kidney failure and heart complications. The man had a rare blood disorder where abnormal cells produced a harmful protein that damaged his kidneys and heart, even though his blood tests showed no signs of the usual blood cell destruction. Despite receiving intensive care, including blood transfusions, powerful immunosuppressants, and therapies designed to block specific parts of the immune system, their conditions continued to worsen. Their organs were failing, and standard medicine had run out of options.
The medical team decided to try a radical approach: autologous haematopoietic stem cell transplantation. This procedure involves collecting a patient's own healthy blood-forming stem cells, freezing them, and then using high-dose chemotherapy to wipe out their existing, malfunctioning immune system. Once the old system is gone, the stored stem cells are returned to the body to grow a new, fresh immune system. It is a high-risk procedure, but for these two patients, it was the last hope. The goal was to reset the body's defense mechanisms, hoping the new immune system would no longer attack the blood vessels or produce the harmful proteins.
The results were striking. In the young woman, the procedure stopped the relentless cycle of clotting and organ damage. Her dangerous antibodies disappeared, and her blood markers returned to normal. She remained free of her original disease for more than eight years, eventually receiving a successful kidney transplant from a donor. In the man, the treatment also brought significant improvement. His kidney function recovered, his blood pressure stabilized, and the harmful protein in his blood decreased substantially. While his original blood disorder was not completely eliminated, the severe damage to his organs halted, and his overall health improved dramatically.
These cases highlight a critical lesson for doctors: the severity of organ damage does not always match the numbers seen in standard blood tests. In the man's case, his blood showed no signs of the typical breakdown of red blood cells, yet his kidneys were being destroyed by the same process. This suggests that relying solely on standard blood markers can be misleading when a disease is confined to specific organs. The doctors learned that when a patient's condition worsens despite normal blood counts, they must look deeper at the specific organs being attacked, such as the heart or kidneys, rather than just the general blood work.
The success of this treatment in these two difficult cases suggests that resetting the immune system with stem cell transplantation could be a viable option for others with severe, treatment-resistant blood vessel disorders. However, the authors caution that this is not a routine cure and carries significant risks. The timing of when to use this therapy remains unclear; it is currently reserved for the most desperate cases where other treatments have failed. While these two stories offer hope, they also serve as a reminder that medicine often requires navigating uncharted territory, where the best path forward is found only after the standard roads have been blocked.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.